ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3,620 | $2,771 | $3,056 |
| - Cash | $258 | $254 | $218 | $320 |
| + Debt | $43 | $56 | $56 | $52 |
| Enterprise Value | – | $3,423 | $2,609 | $2,788 |
| Revenue | $279 | $265 | $244 | $260 |
| % Growth | 5.3% | 8.3% | -5.9% | – |
| Gross Profit | $257 | $244 | $224 | $238 |
| % Margin | 92.2% | 92.2% | 91.7% | 91.6% |
| EBITDA | $48 | $35 | $22 | $12 |
| % Margin | 17.1% | 13.3% | 9.1% | 4.7% |
| Net Income | $72 | $27 | $19 | $144 |
| % Margin | 25.8% | 10.1% | 7.8% | 55.4% |
| EPS Diluted | 0.42 | 0.16 | 0.11 | 0.86 |
| % Growth | 162.5% | 45.5% | -87.2% | – |
| Operating Cash Flow | $74 | $64 | $20 | $40 |
| Capital Expenditures | -$0 | $99 | -$99 | -$0 |
| Free Cash Flow | $74 | $162 | -$79 | $40 |